We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
BA
101
BlackRock Advisors
Delaware
$221K -$10.6M -1,957,385 -98%
CAM
102
Congress Asset Management
Massachusetts
$205K
Bank of Montreal
103
Bank of Montreal
Ontario, Canada
$204K -$769K -142,462 -83%
TCIM
104
TIAA CREF Investment Management
New York
$181K -$5.46M -1,011,190 -97%
WAM
105
Wolverine Asset Management
Illinois
$180K +$137K +25,300 +2,198%
D.E. Shaw & Co
106
D.E. Shaw & Co
New York
$174K -$51.5K -9,543 -27%
Citigroup
107
Citigroup
New York
$150K -$309K -57,172 -72%
MSA
108
Mason Street Advisors
Wisconsin
$149K -$2.92K -540 -2%
AB
109
Amalgamated Bank
New York
$143K +$26K +4,811 +30%
Tudor Investment Corp
110
Tudor Investment Corp
Connecticut
$126K +$99.5K +18,432 New
Commonwealth Equity Services
111
Commonwealth Equity Services
Massachusetts
$124K +$19.2K +3,560 +24%
AG
112
Aperio Group
California
$121K
AIG
113
American International Group
New York
$119K +$54.2K +10,035 +135%
Comerica Bank
114
Comerica Bank
Texas
$119K -$109K -20,177 -54%
TRCT
115
Tower Research Capital (TRC)
New York
$116K +$91.8K +17,004 New
Verition Fund Management
116
Verition Fund Management
Connecticut
$111K +$33.3K +6,173 +61%
VAM
117
Visium Asset Management
New York
$110K -$3.98M -738,029 -98%
ST
118
Stifel Trust
Missouri
$109K +$2.16K +400 +3%
CI
119
Cowen Inc
New York
$102K -$162K -30,000 -67%
TAM
120
Tocqueville Asset Management
New York
$102K -$104K -19,300 -56%
Prudential Financial
121
Prudential Financial
New Jersey
$102K -$4.32K -800 -5%
DTL
122
Dynamic Technology Lab
Singapore
$96K +$2.54K +470 +3%
LCM
123
Landscape Capital Management
New Jersey
$95K +$75K +13,900 New
DCM
124
Driehaus Capital Management
Illinois
$95K +$75.6K +14,000 New
FAM
125
Forty4 Asset Management
Illinois
$93K +$74K +13,700 New

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.